– From the point of view of medicine producers, the dilemmas and challenges, which are faced by the Polish Minister of Health, are enormous today – said Jerzy Toczyski, President of GlaxoSmithKline Pharmaceuticals in Poland during a panel „Effective cooperation for the benefit of health”. – Prices, for both innovative and generic medicines, belong to the lowest in Europe, and in the same time the level of the share in the medicine price covered by patients is one of the highest. The medicine refund policy must be formulated anew.
Participants in the panel agreeably proved that the health ministry, working currently on four laws called „the pharmaceutical package” (refund law, law on registration office, clinical tests and the Pharmaceutical law) should discuss them with all interested parties, to minimize many risks connected with introduction of the new law.
Judith Bidlo, Deputy Director in the Hungarian Supreme Health Insurance Fund, shared the experience of her country in introduction of changes to the refund system. Hungary has a contracting system based on results, the budgets are separate for medicines and hospital treatment, including medicines used during treatment. – We wanted to share the risk between companies and the government. Especially in the case of innovative therapies, there is always a risk if the real examinations would confirm the results of clinical trials – explained Bidlo.
Aurelie Vandeputte from the EC emphasized that the Commission does not work currently on recommendations within the scope of medicine management policy for the member states, it wants only to prepare projects related to health care in consultation with companies, representatives of governments and patients” organizations.
[wyimek]19.4 bln PLN was worth the Polish pharmaceutical market in 2009[/wyimek]
